PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t Cells (NCT05176275) | Clinical Trial Compass
UnknownNot Applicable
PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t Cells
10 participantsStarted 2022-01-01
Plain-language summary
The proliferation and distribution of CD19 CAR-T cells in lymphoma patients are investigated 68Ga-NOTA-RP25 by PET / CT imaging.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 1\. The subjects voluntarily signed the informed consent form and were able to complete the test according to the protocol requirements; 2. Over 18 years old, male or female; 3. Diagnosed as lymphoma and intended to receive CD19 car-t treatment; 4. ECOG score is 0-1; The estimated survival time shall not be less than 3 months;
Exclusion Criteria:
* 1\. Participate in other clinical trials other than CAR-T treatment at the same time or within 28 days. If participating in a non intervention clinical trial, it can be included in this study; 2. Patients with a history of allergy; 3. Patients who cannot tolerant PET / CT imaging; 4. Patients who are using anticoagulant drugs or need to use anticoagulant drugs during the study;
What they're measuring
1
SUV value of radioactive material uptake in the region of interest
Timeframe: 1 month
Trial details
NCT IDNCT05176275
SponsorThe First Affiliated Hospital of Soochow University